Daily Express US on MSN
Jill Biden says she was 'shocked' at Joe Biden's prostate cancer diagnosis
In her forthcoming memoir, former First Lady Jill Biden candidly addresses former President Joe Biden's stage IV prostate ...
Hosted on MSN
Joe Biden delivers first public remarks since prostate cancer diagnosis, says he has ‘no regrets’ about not running
Participating in a Memorial Day commemoration, Joe Biden made his first public address since the announcement of his Stage 4 prostate cancer diagnosis at a Biden family event in his home state of ...
It's not an easy conversation for men to have, but talking about prostate problems is important. Common symptoms include urinary frequency or urgency or difficulty going to the bathroom. For years, ...
The applause was warm, almost celebratory—but beneath it lingered something deeper: relief, survival, and the quiet weight of second chances. What should have been a routine anniversary event in Lagos ...
Israeli leader doesn't say when treatment occurred Netanyahu delayed release of his medical report The prime minister underwent prostate surgery in 2024 Israeli Prime Minister Benjamin Netanyahu said ...
After a two-day hearing where Patterson Belknap’s Steve Zalesin and Jonah Knobler took the lead for Johnson & Johnson, U.S. District Judge Dale Ho in Manhattan held that the study was reliable and ...
The Israeli leader had surgery in 2024 for an enlarged prostate. More recently, follow-up care detected a tumor, his office disclosed on Friday. By David M. Halbfinger Reporting from Jerusalem Prime ...
Real-world, prospective data corroborate trial results showing functional declines after prostate cancer surgery, despite progress in nerve-sparing techniques. Active surveillance best preserves ...
Reductions in hot flashes/day and in daily hot flash scores seen with 2.5mg and 5mg oxybutynin vs placebo. HealthDay News — For men with prostate cancer experiencing androgen deprivation ...
Pharmaceutical giant Johnson & Johnson announced today that its androgen receptor inhibitor apalutamide (Ereleada) led to a 51% reduction in the risk of death over 24 months compared with the androgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results